Proteins specific for CD137

Patent metadata

Field	Value
Publication number	US-12195503-B2
Application number	US-202217579392-A
Country	US
Kind code	B2
Filing date	Jan 19, 2022
Priority date	May 4, 2015
Publication date	Jan 14, 2025
Grant date	Jan 14, 2025

Abstract

The present disclosure provides human lipocalin muteins that bind CD137 and can be used in pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as cancer, infectious diseases, and autoimmune diseases. The present disclosure also concerns methods of making CD137 binding lipocalin muteins described herein as well as compositions comprising such lipocalin muteins. The present disclosure further relates to nucleic acid molecules encoding such lipocalin muteins and to methods for generation of such lipocalin muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these lipocalin muteins as well as compositions comprising one or more of such lipocalin muteins.

First claim

The invention claimed is:

1. A nucleic acid molecule comprising a nucleotide sequence encoding a mutein of human Lipocalin 2 (hNGAL) that binds CD137, wherein the mutein comprises at least 10 of the following mutated amino acid residues in comparison with the linear polypeptide sequence of mature hNGAL (SEQ ID NO: 2): Gln 28→His; Leu 36→Gln; Ala 40→Ile; Ile 41→Arg or Lys; Gln 49→Val, Ile, His, Ser or Asn; Tyr 52→Met; Asn 65→Asp; Ser 68→Met, Ala or Gly; Leu 70→Ala, Lys, Ser or Thr; Arg 72→Asp; Lys 73→Asp; Asp 77→Met, Arg, Thr or Asn; Trp 79→Ala or Asp; Arg 81→Met, Trp or Ser; Phe 83→Leu; Cys 87→Ser; Leu 94→Phe; Asn 96→Lys; Tyr 100→Phe; Leu 103→His; Tyr 106→Ser; Lys 125→Phe; Ser 127→Phe; Tyr 132→Glu; and Lys 134→Tyr, and wherein the mutein comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 12-20.

2. The nucleic acid molecule of claim 1 , wherein the mutein binds CD137 with an affinity measured by a dissociation constant (KD) of about 150 nM or lower.

3. The nucleic acid molecule of claim 1 , wherein the mutein binds CD137 with an affinity measured by a KD of about 10 nM or lower.

4. The nucleic acid molecule of claim 1 , wherein the mutein binds CD137 with an affinity measured by a half maximal effective concentration (EC50) value of about 18 nM or lower.

5. The nucleic acid molecule of claim 1 , wherein the mutein does not interfere with the binding of CD137L to CD137.

6. The nucleic acid molecule of claim 1 , wherein the mutein is capable of enhancing IL-2 secretion.

7. The nucleic acid molecule of claim 1 , wherein the mutein is capable of increasing IFN-gamma production.

8. A host cell containing the nucleic acid molecule of claim 1 , wherein the host cell is a prokaryotic cell selected from the group consisting of Escherichia coli ( E. coli ) and Bacillus subtilis.

9. A host cell containing the nucleic acid molecule of claim 1 , wherein the host cell is a eukaryotic cell selected from the group consisting of Saccharomyces cerevisiae, Pichia pastoris , SF9 or High5 insect cells and immortalized mammalian cell lines.

10. The host cell of claim 9 , wherein the immortalized mammalian cell lines are Hela cells or CHO cells.

11. A host cell containing the nucleic acid molecule of claim 1 , wherein the host cell is a primary mammalian cell.

12. A host cell containing the nucleic acid molecule of claim 1 .

13. The host cell of claim 12 , wherein the host cell is a prokaryotic cell selected from the group consisting of Escherichia coli ( E. coli ) and Bacillus subtilis or the host cell is a eukaryotic cell selected from the group consisting of Saccharomyces cerevisiae, Pichia pastoris , SF9 or High5 insect cells and immortalized mammalian cell lines.

14. A nucleic acid molecule comprising a nucleotide sequence encoding a mutein of human Lipocalin 2 (hNGAL) that binds CD137, wherein the mutein comprises at least 10 of the following mutated amino acid residues in comparison with the linear polypeptide sequence of mature hNGAL (SEQ ID NO: 2): Gln 28→His; Leu 36→Gln; Ala 40→Ile; Ile 41→Arg or Lys; Gln 49→Val, Ile, His, Ser or Asn; Tyr 52→Met; Asn 65→Asp; Ser 68→Met, Ala or Gly; Leu 70→Ala, Lys, Ser or Thr; Arg 72→Asp; Lys 73→Asp; Asp 77→Met, Arg, Thr or Asn; Trp 79→Ala or Asp; Arg 81→Met, Trp or Ser; Phe 83→Leu; Cys 87→Ser; Leu 94→Phe; Asn 96→Lys; Tyr 100→Phe; Leu 103→His; Tyr 106→Ser; Lys 125→Phe; Ser 127→Phe; Tyr 132→Glu; and Lys 134→Tyr, and wherein the mutein comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence shown in SEQ ID NO: 13.

15. The nucleic acid molecule of claim 14 , wherein the mutein has the amino acid sequence of SEQ ID NO: 13.

16. A host cell containing the nucleic acid molecule of claim 14 .

17. The host cell of claim 16 , wherein the host cell is a prokaryotic cell selected from the group consisting of Escherichia coli ( E. coli ) and Bacillus subtilis or the host cell is a eukaryotic cell selected from the group consisting of Saccharomyces cerevisiae, Pichia pastoris , SF9 or High5 insect cells and immortalized mammalian cell lines.

Assignees

• Pieris Pharmaceuticals Gmbh

Inventors

• Hinner Marlon
• Rothe Christine
• Olwill Shane
• Allersdorfer Andrea
• Bel Aiba Rachida Siham

Classifications

• C07K2319/30

  Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto · CPC title

• A61K47/51

  the non-active ingredient being a modifying agent · CPC title

• A61K38/00 Primary

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• C07K14/47 Primary

  from mammals · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title